Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders
Clinical & Experimental Allergy · 2024
DOI: 10.1111/cea.14518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2024. Verfasst von Mutong Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 9 Literaturangaben. Gefördert von: Capital's Fund for Health Improvement and Research, Chinese Association of Rehabilitation Medicine's Fund for Technological Improvement, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
ORCID-Profile: Mutong Zhao
Förderung
- Capital's Fund for Health Improvement and Research
- Chinese Association of Rehabilitation Medicine's Fund for Technological Improvement
- Beijing Natural Science Foundation
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhao, M., Zhuang, Y., Liang, Y., Ma, L., & Shen, C. (2024). Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.14518
Vancouver
Zhao M, Zhuang Y, Liang Y, Ma L, Shen C. Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders. Clinical & Experimental Allergy. 2024. doi:10.1111/cea.14518
BibTeX
@article{Zhao2024,
author = {Zhao, Mutong and Zhuang, Yi and Liang, Yuan and Ma, Lin and Shen, Chunping},
title = {Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real‐World Study on Effectiveness and Safety in Dupilumab Nonresponders},
journal = {Clinical & Experimental Allergy},
year = {2024},
doi = {10.1111/cea.14518}
}
EUVIMED